MagForce AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
MagForce AG Maintains FY 2013 Financial Guidance
MagForce AG announced that based on current developments, the Company is reiterating its outlook for the fiscal year 2013 as published in the 2012 Annual Report. Given the Company's roll-out plan, it expects the net loss from operating activities to be higher than in 2012, largely due to the start of the new clinical glioblastoma study and to preparations for market entry in other countries.
Latest Key Developments in Biotechnology
- Lorus Therapeutics Inc completes $7,001,500 prospectus offering of common shares
- KaloBios Pharmaceuticals Inc announces preliminary phase 1 results in advanced hematologic malignancies with kb004, an anti-epha3 monoclonal antibody
- Zogenix Inc announces FDA approval of four mg SUMAVEL DosePro (sumatriptan injection) needle-free delivery system
- Seattle Genetics Inc highlights ADCETRIS (Brentuximab Vedotin) phase two clinical data in diffuse large B-cell Lymphoma (DLBCL) at ASH 2013
- Share this
- Digg this